Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 30.5
(-4.39%)
SEK 30.5
(-4.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.96 Million SEK | -97.88% |
| 2022 | 234.37 Million SEK | 28.78% |
| 2021 | 181.99 Million SEK | 16.25% |
| 2020 | 156.55 Million SEK | 13.72% |
| 2019 | 137.66 Million SEK | 0.91% |
| 2018 | 136.42 Million SEK | 4.95% |
| 2017 | 129.98 Million SEK | 3.71% |
| 2016 | 125.33 Million SEK | -10.37% |
| 2015 | 139.83 Million SEK | 6.86% |
| 2014 | 130.85 Million SEK | 21.95% |
| 2013 | 107.29 Million SEK | -9.73% |
| 2012 | 118.85 Million SEK | 554.66% |
| 2011 | 18.15 Million SEK | -87.92% |
| 2010 | 150.24 Million SEK | 25.05% |
| 2009 | 120.14 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 68.68 Million SEK | 14.71% |
| 2024 Q1 | 60.21 Million SEK | 8.02% |
| 2024 Q2 | 59.87 Million SEK | -0.56% |
| 2023 Q4 | 55.74 Million SEK | -9.86% |
| 2023 FY | 4.96 Million SEK | -97.88% |
| 2023 Q1 | 65.72 Million SEK | 55.91% |
| 2023 Q2 | 93.86 Million SEK | 42.83% |
| 2023 Q3 | 61.84 Million SEK | -34.12% |
| 2022 Q3 | 65.51 Million SEK | 2.61% |
| 2022 Q4 | 42.15 Million SEK | -35.66% |
| 2022 FY | 234.37 Million SEK | 28.78% |
| 2022 Q1 | 62.84 Million SEK | 43.06% |
| 2022 Q2 | 63.85 Million SEK | 1.6% |
| 2021 Q1 | 45.19 Million SEK | 32.18% |
| 2021 Q3 | 46.62 Million SEK | 0.84% |
| 2021 Q4 | 43.93 Million SEK | -5.78% |
| 2021 FY | 181.99 Million SEK | 16.25% |
| 2021 Q2 | 46.23 Million SEK | 2.31% |
| 2020 Q2 | 43.8 Million SEK | 10.21% |
| 2020 Q1 | 39.75 Million SEK | 16.52% |
| 2020 FY | 156.55 Million SEK | 13.72% |
| 2020 Q3 | 38.8 Million SEK | -11.42% |
| 2020 Q4 | 34.19 Million SEK | -11.88% |
| 2019 FY | 137.66 Million SEK | 0.91% |
| 2019 Q4 | 34.11 Million SEK | -0.56% |
| 2019 Q3 | 34.3 Million SEK | -3.47% |
| 2019 Q2 | 35.54 Million SEK | 5.34% |
| 2019 Q1 | 33.73 Million SEK | 26.27% |
| 2018 Q3 | 31.22 Million SEK | -29.34% |
| 2018 Q4 | 26.72 Million SEK | -14.43% |
| 2018 FY | 136.42 Million SEK | 4.95% |
| 2018 Q1 | 34.28 Million SEK | 10.33% |
| 2018 Q2 | 44.19 Million SEK | 28.9% |
| 2017 Q4 | 31.07 Million SEK | -1.11% |
| 2017 Q3 | 31.42 Million SEK | -9.45% |
| 2017 FY | 129.98 Million SEK | 3.71% |
| 2017 Q2 | 34.7 Million SEK | 5.83% |
| 2017 Q1 | 32.79 Million SEK | 20.66% |
| 2016 Q3 | 31.32 Million SEK | -6.61% |
| 2016 Q4 | 27.17 Million SEK | -13.24% |
| 2016 Q1 | 33.29 Million SEK | 4877.43% |
| 2016 FY | 125.33 Million SEK | -10.37% |
| 2016 Q2 | 33.53 Million SEK | 0.72% |
| 2015 Q3 | 32.89 Million SEK | -25.27% |
| 2015 Q1 | 62.25 Million SEK | 77.42% |
| 2015 FY | 139.83 Million SEK | 6.86% |
| 2015 Q2 | 44.01 Million SEK | -29.3% |
| 2015 Q4 | 669 Thousand SEK | -97.97% |
| 2014 Q2 | 34.88 Million SEK | 14.4% |
| 2014 Q4 | 35.09 Million SEK | 15.47% |
| 2014 FY | 130.85 Million SEK | 21.95% |
| 2014 Q3 | 30.38 Million SEK | -12.88% |
| 2014 Q1 | 30.49 Million SEK | 28.58% |
| 2013 Q3 | 32.45 Million SEK | 36.42% |
| 2013 Q4 | 23.71 Million SEK | -26.93% |
| 2013 Q1 | 27.33 Million SEK | 5.15% |
| 2013 Q2 | 23.78 Million SEK | -12.99% |
| 2013 FY | 107.29 Million SEK | -9.73% |
| 2012 Q2 | 27.58 Million SEK | 0.0% |
| 2012 FY | 118.85 Million SEK | 554.66% |
| 2012 Q4 | 26 Million SEK | -15.3% |
| 2012 Q3 | 30.69 Million SEK | 11.27% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | 18.15 Million SEK | -87.92% |
| 2010 FY | 150.24 Million SEK | 25.05% |
| 2009 FY | 120.14 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 94.002% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.188% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 99.188% |
| Arcoma AB | 53.25 Million SEK | 90.669% |
| BICO Group AB (publ) | 2.84 Billion SEK | 99.826% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 97.639% |
| CellaVision AB (publ) | 295.99 Million SEK | 98.321% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 92.791% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -279.55% |
| C-Rad AB (publ) | 3.8 Million SEK | -30.763% |
| Duearity AB (publ) | 21.58 Million SEK | 76.979% |
| Dignitana AB (publ) | 74.73 Million SEK | 93.351% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -84.037% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.954% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | 72.741% |
| Iconovo AB (publ) | 63.35 Million SEK | 92.157% |
| Integrum AB (publ) | 90.57 Million SEK | 94.514% |
| Luxbright AB (publ) | 23.09 Million SEK | 78.48% |
| Mentice AB (publ) | 237.06 Million SEK | 97.904% |
| OssDsign AB (publ) | 175.6 Million SEK | 97.17% |
| Paxman AB (publ) | 133.8 Million SEK | 96.286% |
| Promimic AB (publ) | 48.55 Million SEK | 89.766% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 96.94% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 92.899% |
| ScandiDos AB (publ) | 61.03 Million SEK | 91.859% |
| Sectra AB (publ) | 39.06 Million SEK | 87.28% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 97.153% |
| Senzime AB (publ) | 141.51 Million SEK | 96.489% |
| SpectraCure AB (publ) | 12.12 Million SEK | 59.029% |
| Stille AB | 87.21 Million SEK | 94.303% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 99.911% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 98.873% |